Skip to main content

Table 2 Baseline characteristics of hemodialysis patients presented as groups according to MBL levels

From: Strong predictive value of mannose-binding lectin levels for cardiovascular risk of hemodialysis patients

MBL range (ng/mL)

Patients

P* < 0.001

R

P#

All (n = 107)

MBL low 319 <  ng/mL (n = 26)

MBL high 319 ≥  ng/mL (n = 81)

821[319–1477]

98[33–146]

1290[671–1848]

Demographics

Age, years

62.5 ± 15.6

65.3 ± 12.1

61.56 ± 16.6

0.3

–0.26

0.007

Male gender, n (%)

71 (66)

17 (65)

54 (67)

1.0

  

Current diabetes, n (%)

25 (24)

9 (35)

16 (20)

0.2

  

Hypertension, n (%)

85 (84)

22 (88)

63 (83)

0.8

  

Cardiovascular history, n (%)

26 (25)

9 (35)

15 (19)

0.1

  

BMI, kg/m2

25.8 ± 4.4

27.0 ± 4.5

25.4 ± 4.4

0.1

–0.03

0.8

Hemodialysis

Dialysis vintage, months

25.5 [8.5–52.3]

18.2 [7.0–47.7]

32.8 [9.1–53.3]

0.2

–0.01

0.9

Primary renal disease, n (%)

Hypertension

18 (17)

4 (15)

14 (17)

1.0

  

Diabetes

14 (13)

5 (19)

9 (11)

0.3

  

ADPKD

13 (12)

3 (12)

10 (12)

1.0

  

FSGS

9 (8)

4 (15)

5 (6)

0.2

  

IgA nephropathy

4 (4)

0 (0)

4 (5)

0.6

  

Chronic pyelonephritis

3 (3)

0 (0)

3 (4)

1.0

  

Glomerulonephritis

13 (12)

2 (8)

11 (14)

0.7

  

Other diagnoses

16 (16)

6 (23)

10 (12)

0.2

  

Unknown

17 (16)

2 (8)

15 (19)

0.2

  

Ultrafiltration volume, L

2.55 ± 0.78

2.54 ± 0.82

2.56 ± 0.78

0.9

–0.01

0.9

Ultrafiltration rate, ml/kg/h

8.56 ± 2.63

7.81 ± 2.39

8.80 ± 2.67

0.1

0.04

0.7

Systolic blood pressure

Predialysis, mmHg

140.4 ± 25.1

144.7 ± 26.4

139.1 ± 24.7

0.3

–0.17

0.08

Postdialysis, mmHg

131.8 ± 25.6

136 ± 24.3

130.4 ± 26.0

0.4

–0.24

0.02

Heart rate

Predialysis, bpm

73 [63–82]

71 [62–82]

74 [64–82]

0.3

0.11

0.3

Postdialysis, bpm

79 [69–87]

75 [65–86]

79 [69–88]

0.4

0.13

0.2

Kidney transplant, n (%)

21 (20)

4 (15)

17 (21)

0.8

  

Laboratory measurements

Hematocrit,  %

34.9 ± 3.8

34.5 ± 4.1

35.0 ± 3.7

0.6

0.04

0.7

HbA1c, mmol/mol

5.68 ± 0.98

5.80 ± 0.97

5.63 ± 0.98

0.5

–0.15

0.2

Albumin, g/L

39 [37–42]

39 [37–42]

39 [37–42]

0.9

0.01

0.9

pH

7.37 [7.34–7.39]

7.37 [7.32–7.39]

7.37 [7.34–7.39]

0.7

0.05

0.6

Calcium, mmol/L

2.31 ± 0.16

2.31 ± 0.15

2.32 ± 0.16

0.9

0.03

0.7

Phosphate, mmol/L

1.67 ± 0.53

1.82 ± 0.47

1.65 ± 0.54

0.2

–0.00

0.9

hsCRP, mg/L

6.7 [2.8–10.9]

6.1 [1.4–12.0]

6.7 [3.0–10.9]

0.7

0.10

0.3

Medication

Aspirin, n (%)

57 (54)

11 (42)

46 (64)

0.3

  

Calcium channel blockers, n (%)

14 (13)

3 (12)

11 (14)

1.0

  

β-Blocker, n (%)

61 (57)

18 (69)

43 (53)

0.2

  

ACE inhibitor, n (%)

10 (10)

3 (12)

7 (9)

0.7

  

AT2-receptor antagonists, n (%)

14 (13)

2 (8)

12 (15)

0.5

  

Statin, n (%)

20 (19)

5 (19)

15 (19)

1.0

  

Diuretics, n (%)

8 (8)

3 (12)

5 (6)

0.4

  
  1. Italic values used to show which statistical testing was significant (below 0.05)
  2. BMI body mass index; ADPKD autosomal dominant polycystic kidney disease; FSGS focal segmental glomerulosclerosis; HbA1c Hemoglobin A1c; pH potential hydrogen; hsCRP high sensitive C-reactive protein; ACE inhibitor angiotensin-converting-enzyme inhibitor; AT2 receptor antagonists, Angiotensin II receptor antagonists
  3. P* indicates P-value for the difference in baseline characteristics between the MBL groups, tested by Student’s t-Test or Mann–Whitney U test for continuous variables and with χ2 test for categorical variables; R indicates Spearman correlation coefficient between MBL levels and the baseline characteristic; # P indicates the corresponding P-value
  4. Data are presented as mean ± SD or median [IQR]
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us